HERQ-9 Is a New Multiplex PCR for Differentiation and Quantification of All Nine Human Herpesviruses by Pyöriä, Lari et al.
HERQ-9 Is a New Multiplex PCR for Differentiation and
Quantification of All Nine Human Herpesviruses
Lari Pyöriä,a Maija Jokinen,a,b Mari Toppinen,a Henri Salminen,a Tytti Vuorinen,c,d Veijo Hukkanen,c
Constanze Schmotz,a Endrit Elbasani,e Päivi M. Ojala,e,f Klaus Hedman,a,g Hannamari Välimaa,a,h
Maria F. Perdomoa
aDepartment of Virology, University of Helsinki, Helsinki, Finland
bDepartment of Evolutionary Biology and Environmental Studies, University of Zürich, Zürich, Switzerland
cInstitute of Biomedicine, University of Turku, Turku, Finland
dClinical Microbiology, Turku University Hospital, Turku, Finland
eTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
fDepartment of Infectious Diseases, Imperial College London, London, United Kingdom
gHelsinki University Hospital, HUSLAB, Helsinki, Finland
hDepartment of Oral and Maxillofacial Surgery, Helsinki University Hospital, Helsinki, Finland
Hannamari Välimaa and Maria F. Perdomo contributed equally to this work.
ABSTRACT Infections with the nine human herpesviruses (HHVs) are globally preva-
lent and characterized by lifelong persistence. Reactivations can potentially manifest
as life-threatening conditions for which the demonstration of viral DNA is essential.
In the present study, we developed HERQ-9, a pan-HHV quantitative PCR designed
in triplex reactions to differentiate and quantify each of the HHV-DNAs: (i) herpes
simplex viruses 1 and 2 and varicella-zoster virus; (ii) Epstein-Barr virus, human cyto-
megalovirus, and Kaposi’s sarcoma-associated herpesvirus; and (iii) HHV-6A, -6B, and
-7. The method was validated with prequantified reference standards as well as with
mucocutaneous swabs and cerebrospinal fluid, plasma, and tonsillar tissue samples.
Our findings highlight the value of multiplexing in the diagnosis of many unsus-
pected, yet clinically relevant, herpesviruses. In addition, we report here frequent
HHV-DNA co-occurrences in clinical samples, including some previously unknown.
HERQ-9 exhibited high specificity and sensitivity (LOD95s of 10 to 17 copies/reac-
tion), with a dynamic range of 101 to 106 copies/l. Moreover, it performed accu-
rately in the coamplification of both high- and low-abundance targets in the same
reaction. In conclusion, we demonstrated that HERQ-9 is suitable for the diagnosis of
a plethora of herpesvirus-related diseases. Besides its significance to clinical manage-
ment, the method is valuable for the assessment of hitherto-unexplored synergistic
effects of herpesvirus coinfections. Furthermore, its high sensitivity enables studies
on the human virome, often dealing with minute quantities of persisting HHVs.
IMPORTANCE By adulthood, almost all humans become infected by at least one
herpesvirus (HHV). The maladies inflicted by these microbes extend beyond the ini-
tial infection, as they remain inside our cells for life and can reactivate, causing se-
vere diseases. The diagnosis of active infection by these ubiquitous pathogens in-
cludes the detection of DNA with sensitive and specific assays. We developed the
first quantitative PCR assay (HERQ-9) designed to identify and quantify each of the
nine human herpesviruses. The simultaneous detection of HHVs in the same sample
is important since they may act together to induce life-threatening conditions. More-
over, the high sensitivity of our method is of extreme value for assessment of the
effects of these viruses persisting in our body and their long-term consequences on
our health.
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The nine human herpesviruses (HHVs) are ubiquitous pathogens that persist lifelongafter primary infection. HHVs cause many disorders, ranging from mild mucocuta-
neous diseases to severe central nervous system conditions, birth defects, and cancer.
Their ability to reactivate poses significant risks, particularly to immunosuppressed
patients, such as transplant recipients, in whom Epstein-Barr virus (EBV), human cyto-
megalovirus (HCMV), HHV-6B, and Kaposi’s sarcoma-associated herpesvirus (KSHV) can
induce life-threatening conditions (1–8).
The investigation of active HHV infections includes, among other markers, the
detection of viral nucleic acids, typically by quantitative PCR (qPCR). In addition, the
simultaneous detection of these pathogens has been shown to be beneficial, as
their recognition may be difficult based on the clinical presentation alone (9–15).
While several multiplex qPCRs have been introduced for detection of HHVs (16–19),
none are designed to quantify them all. In addition, only few of the existing protocols
distinguish between the closely related HHV-6A and HHV-6B, a distinction that may be
crucial, as the former still lacks clear association to disease (20–23).
In the present study, we developed a pan-herpes multiplex assay, HERQ-9, that
quantifies and discriminates each of the HHVs using three separate triplex-qPCRs: the
first amplifies herpes simplex viruses 1 and 2 (HSV-1 and -2) and varicella-zoster virus
(VZV), the second EBV, HCMV, and KSHV, and the third HHV-6A, -6B, and -7. We
validated our assay using prequantified reference materials and evaluated its perfor-
mance with various clinical samples as well as solid tissue material.
HERQ-9 simplifies diagnosis and improves the clinical management and risk assessment
of highly susceptible populations (1, 5, 8, 24–26). Moreover, its high sensitivity is of
significant value for studies on the impact of HHV persistence on health (27, 28) and disease
(29, 30).
RESULTS
In silico evaluation of amplicons, primers, and probes. The designed primers and
probes were queried against all available sequences (full or partial genomes) in the
NCBI database. The oligonucleotides showed perfect match for the different strains
except for four sequences of HHV-6A (GenBank accession numbers KY316054.1,
KT355575.1, KY316056.1, and KY316047.1) and two of HCMV (GenBank accession
numbers KY490070.1 and KP745685.1) for which one to two mismatches were observed
far from the 3= end.
We found no nonspecific binding to other viruses or human DNA except for the
primers and probe of HSV-2, which also had complete homology to chimpanzee
alpha-1 herpesvirus (GenBank accession number JQ360576.1).
In silico analysis of amplicons, primers, and probes revealed no relevant secondary
structures, primer-dimers, or cross-dimers (see Fig. S1 and S2 in the supplemental
material).
Analytical sensitivities and specificities.We evaluated the sensitivities using eight
replicates of the respective plasmids in seven dilutions ranging from 50 copies to 1
copy per reaction. Based on probit link function, the limits of detection (LOD95) of
HERQ-9 for HSV-1, HSV-2, VZV, EBV, HCMV, KSHV, HHV-6A, HHV-6B, and HHV-7 were,
respectively, 12, 13, 13, 10, 16, 17, 11, 11, and 11 copies per reaction. The values were
similar in the singleplex format (see Fig. S3 in the supplemental material).
The multiplex assay detected all HHVs correctly from infected cell lines without
cross-amplification of other HHVs, human DNA, or near-full-length or full-length ge-
nomes of parvovirus B19 (B19V) or the polyomaviruses BK virus (BKPyV), JC virus
(JCPyV), and Merkel cell virus (MCPyV). All the no-template water controls remained
negative throughout the PCR analyses.
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Repeatability and reproducibility. We tested the intra-assay and interassay vari-
ations in three separate qPCR runs using five replicates of the individual HHV plasmids
(106 to 101 copies/l) and plasmid mixes pMIXI (HSV-1 and -2 and VZV), pMIXII (EBV,
HCMV, and KSHV), and pMIXIII (HHV-6A, -6B, and -7).
The assay showed excellent short-term repeatability and long-term reproducibility in
both singleplex and multiplex formats as well as with pMIXI to -III. The highest standard
deviations in quantification cycle (Cq) values (intra-assay) and coefficients of variation
between runs (interassay) were seen at the lowest template copies (Tables 1 and 2).
The method was linear in the range of 101 to 106 copies per l, and the qPCR
efficiencies were between 95.9% and 103.8% in all the experiments.
The HHV plasmid dilutions spiked with 500 ng of human DNA (HaCaT cells) showed
equal linearity to pure HHV plasmids (Fig. 1; see also Fig. S4 in the supplemental material).
Comparison to prequantified reference samples. We correlated the quantifica-
tion of HERQ-9 to several prequantified reference materials. The results are summarized
in Table 3.
TABLE 1 Intra-assay variation
Virus and format
Mean Cq value  SD by no. of copies/l
Efficiency (%) R2 Slope Intercept101 102 103 104 105 106
HSV-1
Singleplex 33.2  0.4 30.3  0.3 26.9  0.1 23.4  0.1 20.1  0.1 16.9  0.1 100.1 0.998 3.32 39.1
Multiplex 33.2  0.4 30.3  0.3 26.8  0 23.3  0.1 20.1  0 17.1  0.2 101.7 0.997 3.28 38.9
pMIXI 33.1  0.1 30.5  0.3 26.9  0.1 23.5  0.2 20.3  0.2 16.8  0.2 100.3 0.997 3.32 39.1
HSV-2
Singleplex 32.4  0.7 29.2  0.2 26.1  0.3 22.6  0.2 19.4  0.4 16.3  0.2 101 0.994 3.3 38.3
Multiplex 32.4  0.6 29.1  0.2 25.8  0.1 22.6  0.2 19.2  0.1 16.1  0.1 101.7 0.997 3.28 38.9
pMIXI 32.9  0.6 29.4  0.3 25.9  0.1 22.5  0.2 19.2  0.1 16  0.2 100.5 0.998 3.31 38.2
VZV
Singleplex 32.0  0.4 28.9  0.2 25.7  0.2 22.1  0.2 18.8  0.1 15.8  0.1 103.2 0.997 3.25 37.5
Multiplex 32.5  0.3 28.8  0.2 25.5  0.1 22.1  0.2 18.9  0.4 15.8  0.2 100.9 0.997 3.3 37.8
pMIXI 32.1  0.4 28.7  0.2 25  0.3 22  0.1 18.8  0.1 15.6  0.2 100.7 0.997 3.31 37.6
EBV
Singleplex 32.6  0.4 29.0  0.5 25.6  0.1 22.3  0.3 18.9  0.1 15.7  0.1 97.8 0.998 3.37 38.2
Multiplex 32.6  0.5 29.0  0.2 25.7  0.1 22.1  0.1 18.9  0.2 15.6  0.1 99.5 0.998 3.33 37.9
pMIXII 32.6  0.6 29.1  0.2 25.5  0.1 22  0.2 18.8  0.2 15.5  0.2 98.6 0.999 3.36 37.9
HCMV
Singleplex 33.9  0.4 30.3  0.3 26.9  0.1 23.7  0.1 20.4  0.2 16.9  0.1 98.2 0.997 3.37 39.5
Multiplex 33.5  0.7 30.4  0.4 26.9  0.2 23.6  0.2 20.3  0.1 16.8  0.1 98.4 0.994 3.36 39.4
pMIXII 33.6  0.4 30.6  0.3 27.0  0.3 23.7  0.2 20.4  0.1 17.0  0.1 99.7 0.996 3.33 39.3
KSHV
Singleplex 33.6  0.8 29.4  0.4 25.8  0.1 22.6  0.2 19.3  0.1 16.1  0.1 95.9 0.996 3.42 38.8
Multiplex 32.6  0.8 29.3  0.5 26.1  0.2 22.6  0.2 19.1  0.1 16.0  0.1 98.9 0.992 3.35 38.3
pMIXII 32.9  0.7 28.9  0.4 25.7  0.2 22.4  0.1 19.0  0.2 15.5  0.2 97.2 0.996 3.39 38.3
HHV-6A
Singleplex 32.4  0.6 29.5  0.3 26.1  0.2 22.7  0.1 19.2  0.1 16.3  0.1 100.6 0.995 3.31 38.3
Multiplex 33.0  0.4 29.5  0.4 25.8  0.1 22.5  0.1 19.4  0.2 16.6  0.1 100.2 0.995 3.32 38.4
pMIXIII 33.3  0.6 29.6  0.3 26.1  0.3 22.9  0.2 19.6  0.2 16.1  0.1 98.2 0.995 3.37 38.7
HHV-6B
Singleplex 31.6  0.9 28.7  0.4 25.3  0.1 21.8  0.2 18.6  0.1 15.6  0.1 100.3 0.992 3.32 37.6
Multiplex 31.8  0.5 28.6  0.2 25.3  0.1 22.0  0.2 18.8  0.2 15.7  0.1 103.8 0.998 3.23 37.4
pMIXIII 31.5  0.5 29.1  0.3 25.6  0.2 22.2  0.1 19  0.2 15.8  0.1 101.9 0.998 3.28 37.7
HHV-7
Singleplex 31.5  0.7 28.1  0.4 25  0.1 21.6  0.2 18.1  0.1 15.0  0.2 100.7 0.995 3.31 37.01
Multiplex 31.6  0.7 28.2  0.4 24.9  0 21.5  0.1 18.2  0.1 15.2  0.1 102.7 0.993 3.26 36.9
pMIXIII 32.2  0.7 28.3  0.1 25.0  0.1 21.5  0.2 18.4  0.1 15.1  0.1 98.2 0.994 3.37 37.5
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DNA from each of the two strains of HSV-1 and HSV-2 had spectrophotometrically
estimated quantities of 4.3  109 and 6.1  109 copies/l and 1.9  109 and 3.8  109
copies/l, respectively. The calculated loads by our multiplex qPCR were 4.2  109 and
6.1  109 copies/l for HSV-1 and 9.1  108 and 1.9  109 copies/l for HSV-2. The
conversion factors were hence 0.99 (HSV-1) and 0.49 (HSV-2).
A VZV DNA extract (ATCC) containing 5.6  105 copies/l was calculated to have
1.8  106 copies/l by HERQ-9, with a conversion factor of 3.2.
EBV, HCMV, and HHV-6B WHO international standards contained 1.0  104, 1.0 
104, and 1.1  105 IU/l, respectively. The calculated copies by HERQ-9 were 1.0  104
copies/l for EBV, 3.2  104 copies/l for HCMV, and 1.8  105 copies/l for HHV-6B.
Hence, the conversion factors (copies/international unit) were 1.0, 3.2, and 1.6, respec-
tively.
Spectrophotometrically estimated copies of KSHV DNA were 2.2  109 copies/l
and calculated to be 5.0  109 copies/l with our assay, yielding a conversion factor
of 2.3.
TABLE 2 Interassay variation
Virus and format
Coefficient of variation (%) by no. of copies/l
101 102 103 104 105 106
HSV-1
Singleplex 12 21 8 4 6 7
Multiplex 16 20 15 7 3 4
pMIXI 7 12 7 4 1 10
HSV-2
Singleplex 23 12 11 9 4 9
Multiplex 27 10 3 2 9 6
pMIXI 33 8 7 9 5 3
VZV
Singleplex 14 6 11 4 2 5
Multiplex 27 9 6 8 2 9
pMIXI 13 16 13 2 8 7
EBV
Singleplex 24 11 11 12 11 7
Multiplex 23 4 10 1 2 4
pMIXII 20 7 4 12 4 14
HCMV
Singleplex 15 13 9 11 18 10
Multiplex 14 9 6 2 3 6
pMIXII 16 8 5 7 12 3
KSHV
Singleplex 15 13 9 11 18 10
Multiplex 14 9 6 2 3 6
pMIXII 16 8 5 7 12 3
HHV-6A
Singleplex 15 7 14 9 3 12
Multiplex 4 19 9 3 1 15
pMIXIII 20 7 7 6 2 0
HHV-6B
Singleplex 27 22 13 4 3 6
Multiplex 28 13 3 12 3 11
pMIXIII 19 5 6 10 6 4
HHV-7
Singleplex 19 10 11 9 8 3
Multiplex 25 4 9 10 2 8
pMIXIII 31 14 12 3 4 14
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HERQ-9 showed good correlation with HHV-6A, HHV-6B, and HHV-7 spiked in sera
(Fig. 2). The conversion factors were 1.1, 1.3, and 6.8, respectively.
Analysis of clinical samples. We tested several types of clinical samples and
compared the positive and negative agreements against reference methods. A sum-
mary of the results is presented in Table 4.
(i) Plasma. We tested 60 plasma samples, previously studied for EBV and/or HCMV
at Turku University Hospital. Altogether, 13/13 and 16/16 plasma samples positive for
EBV and HCMV by a reference qPCR, respectively, were positive by HERQ-9, with good
correlation in viral loads (Fig. 3). Seven out of nine samples reported as borderline for
EBV by the clinical laboratory (50 to 200 copies/ml of plasma) were positive in the new
assay, as were four of five HCMV-borderline samples (50 to 200 copies/ml of plasma).
Furthermore, the new qPCR found additional samples positive for EBV (n 3) and
HCMV (n 5) that in the hospital laboratory had been tested only for one of the viruses.
These samples were reanalyzed with a reference qPCR confirming one EBV and three
HCMV positivities.
FIG 1 (A) Amplification and standard curves of HSV-1 plasmid dilutions from 106 to 101 copies/l in singleplex format (red) or in multiplex format individually
(green) or together with HSV-2 and VZV plasmids (pMIXI; blue). (B) pMIXI dilution series spiked with 500 ng/reaction of human DNA (HaCaT cells). The y axis
represents baseline-corrected fluorescence signal (amplification curve) or cycles (standard curve). The x axis represents cycle number (amplification curve) or
plasmid copies in the reaction (log10) (standard curve). Analogous illustrations for other herpesviruses can be found in Fig. S4.
TABLE 3 Prequantified reference material
Virus Sample type
Quantification
method Strain(s)
GenBank
accession no.
No. of copies/l
Conversion
factor
Difference between
quantifications (log10)Reference HERQ-9
HSV-1 DNA from purified
nucleocapsids
Spectrophotometer HSV-H1211,
HSV-H1215
MH999843,
MH999846
4.3  109,
6.1  109
4.2  109,
6.1  109
0.99 0.02
HSV-2 DNA from purified
nucleocapsids
Spectrophotometer HSV2-H12211,
HSV2-H1526
KY922725,
KY922724
1.9  109,
3.8  109
9.1  108,
1.9  109
0.49 0.31
VZV Quantified DNA,
ATCC
ddPCRa Ellen JQ972913.1 5.6  105 1.8  106 3.2 0.51
EBV WHO international
standard
qPCR (NIBSC code
09/260) (57)
B95-8 NC_007605 1.0  104 1.0  104 1.0 0.02
HCMV WHO international
standard
qPCR (NIBSC code
09/162) (58)
Merlin GU179001.1 1.0  104 3.2  104 3.2 0.51
KSHV Genome in BAC Spectrophotometer BAC16 JSC-1 MK208323.1 2.2  109 5.0  109 2.3 0.36
HHV-6A Spiked serum,
HHV-6 Foundation
qPCR (59) GS KC465951.1 1.6  104 to
1.6  100
2.1  104 to
1.1  100
1.1 0.03
HHV-6B WHO international
standard
qPCR (NIBSC code
15/266) (59)
Z29 AF157706.1 1.1  105 1.8  105 1.6 0.20
HHV-7 Spiked serum,
HHV-6 Foundation
HHV-7 qPCR kit
(PCRmax)
JI U43400.1 1.7  102 to
2.4  101
1.1  103 to
2.4  100
6.8 0.83
addPCR, droplet digital PCR.
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Of the 60 plasma samples studied with HERQ-9, 6 were positive for HHV-6B (median,
2.7 102 copies/ml of plasma; range, 1.7 102 to 5.2 103), 1 was positive for HHV-6A
(6.3  102 copies/ml of plasma), and 5 were positive for HSV-1 (median, 1.2  104
copies/ml of plasma; range, 8.0  102 to 5.1  104). The co-occurrence of HHVs in
plasma was seen for 14 patients, of whom 3 had EBV/HCMV/HSV-1, 1 had EBV/HCMV/
HHV-6B, 1 had EBV/HHV-6B/HSV-1, 5 had EBV/HCMV, 2 had EBV/HHV-6B, 1 had HCMV/
HHV-6B, and 1 had EBV/HSV-1 (Fig. 4A).
(ii) Mucocutaneous swabs. We tested 114 mucocutaneous swab samples previ-
ously investigated for HSV-1 and -2 or VZV at Turku University Hospital.
HERQ-9 identified correctly all the mucocutaneous swab samples that had tested
positive by rapid viral culture for HSV-1 (n 35; median, 5.6  107; range, 1.4  105 to
8.2 109 copies/ml of collection medium) and HSV-2 (n 30; median, 3.3 107; range,
2.9  105 to 3.5  108 copies/ml of collection medium). In contrast, the 15 culture-
FIG 2 Reference copy numbers of serum samples spiked with HHV-6A (A), HHV-6B (B), and HHV-7 (C)
plotted against copy numbers quantified by HERQ-9. Viral DNA copy numbers are presented per milliliter
of serum (log10 transformed). R2, coefficient of determination between the copy numbers.
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negative controls showed no amplification for HSV-1 or HSV-2. However, two of these
negative samples were positive instead for VZV, at 2.0  107 and 3.2  104 copies/ml
of collection medium, and were confirmed to be VZV DNA positive with a control PCR
(4, 31). In addition, 5/5 HSV-1-positive and 4/4 HSV-2-positive DNA extracts previously
tested by a reference PCR (4, 31) were also positive by HERQ-9.
TABLE 4 Clinical samples and other sample material
Virus
Clinical samples Other sample material
Sample type n Reference method(s)
Positive
agreement
Negative
agreement Type Strain(s)
GenBank
accession no.
HSV-1 Mucocutaneous
swab
92 Rapid viral culture
immunoperoxidase,
qPCR (4, 31, 53)
42/42 (100%) 49/50 (98%) Infected cell
cultures
Strain F KM222724.1
HSV-2 Mucocutaneous
swab
Rapid viral culture
immunoperoxidase,
qPCR (4, 31, 53)
34/34 (100%) 58/58 (100%) Infected cell
cultures
Strain G KP143740.1
VZV Mucocutaneous
swab
27 EIA, qPCR (4, 31, 61) 20/20 (100%) 14/15 (93.3%) Infected cell
cultures
Ellen JQ972913.1
CSF 8
EBV Plasma 46 GeneProof EBV PCR kit 14/14 (100%); 7/9a 21/23 (91.3%) Raji cells Raji KF717093.1
HCMV Plasma 48 GeneProof CMV PCR kit 19/19 (100%); 4/5a 22/24 (91.7%) Infected cell
cultures
AD169 FJ527563.1
KSHV Infected cell
cultures
JSC-1 clone
BAC16
GQ994935.1
HHV-6A Infected cell
cultures
GS KC465951.1
HHV-6B Spiked serum,
infected cell
cultures
Z29 AF157706.1
HHV-7 Infected cultures JI U43400.1
aPositive agreement with samples reported borderline with reference assay.
FIG 3 Comparison of EBV (A) and HCMV (B) quantities (copies/milliliter of plasma in log10) as determined
by HERQ-9 and GeneProof EBV and CMV PCR kit reference assays.
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All the VZV samples positive (n 15) by enzyme immunoassay (EIA) were positive
by the new assay, at a median quantity of 4.5  107 copies/ml of collection medium
(range, 8.0  106 to 2.7  109). On the other hand, among 10 VZV antigen-negative
samples, 2 contained VZV DNA at 3.6  106 and 4.7  103 copies/ml of collection
medium. Of these, the former was confirmed to be VZV DNA positive by the reference
PCR. Incidentally, among the remaining eight samples negative for the VZV antigen,
three showed positivity for HSV-1 instead, at loads of 7.7  107, 7.2  107, and 6.3 
101 copies/ml of collection medium. Only the two samples with the highest copy
numbers were confirmed to be positive for HSV-1 DNA by the control PCR.
Moreover, we codetected other HHVs in these mucocutaneous swabs (Fig. 4C and
D). Of the HSV-1-positive samples, 20.9% were also positive for EBV DNA, 4.7% for
FIG 4 Venn diagrams representing HHV co-occurrence in 60 plasma samples (A), 35 palatine tonsils (B), 43 HSV-1-positive mucocutaneous swab samples (C),
and 34 HSV-2-positive mucocutaneous swab samples (D). n, number of positive cases.
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HCMV DNA, 9.3% for HHV-7 DNA, and 2.3% for HHV-6B DNA. Among the HSV-2-positive
swabs, 5.3% were also positive for EBV, 8.8% for HCMV, and 2.9% for HHV-7. Of 19
VZV-positive swabs, 1 was positive for EBV-DNA (5.3%). Of all the 114 swabs, 2 were
quadruply positive (HSV-1/EBV/HCMV/HHV-7 and HSV-2/EBV/HCMV/HHV-7) and 4 were
triply positive (HSV-1/EBV/HCMV, HSV-1/HHV-6B/HHV-7, and two HSV-2/EBV/HCMV).
The copy numbers of the other codetected HHVs (generally log2 to log3 copies/ml of
collection medium) were always lower than those for HSV-1, HSV-2, or VZV. However,
a few samples had log5 to log6 copies/ml of EBV DNA. Of all the mucocutaneous
swab samples negative for HSV-1, HSV-2, and VZV (n 18), one (5.6%) tested
positive for EBV DNA.
(iii) CSF. Eight cerebrospinal fluid (CSF) samples were analyzed with the pan-herpes
multiplex assay. Two were positive for VZV (3.23  103 and 1.64  105 copies/ml of
CSF), in concordance with the hospital laboratory reference PCR (4, 31).
HHV prevalences in tonsillar tissue. The HHV DNA prevalences in 35 tonsillar
tissue samples were 80% for HHV-7, 71% for EBV, 66% for HHV-6B, 3% for HSV-1, and
3% for HCMV. No HSV-2, VZV, or KSHV was found (Fig. 5). Of these samples, 2 were
positive for four HHVs, 17 for three, and 10 for two, while four tonsils were negative for
all the HHVs (Fig. 4B). The median viral loads (copies/million cells) were highest for EBV
(2.1  102; interquartile range [IQR], 9.6  102), followed by HHV-7 (3.6  101; IQR,
1.3  102) and HHV-6B (1.1  101; IQR, 2.2  101).
Coquantification of mixed high- and low-abundance targets. We tested uneven
copies of whole HHV genomes in the same reaction (range, 4.5  100 to 1.1  106
copies/l) and found that all the viruses were correctly differentiated and accurately
quantified by HERQ-9 (Pearson correlation coefficient [r]  0.996, P 0.01). Higher
coefficients of variation were seen at lower viral copy numbers (Table 5).
DISCUSSION
Our newly developed pan-herpes multiplex-qPCR assay, HERQ-9, stands out for its
ability to differentiate and quantify the genomes of all nine human herpesviruses.
HERQ-9 was designed on three distinct triplex-qPCRs to meet, on the one hand, the
clinical needs and, on the other, the technical constraints inherent to PCR multiplexing.
Indeed, the capacity to codetect several targets is restricted by the spectral overlap of
different fluorophores as well as the number of channels in the qPCR instrument
FIG 5 Prevalences and copy numbers per million cells of HHV-6B, HHV-7, EBV, HSV-1, and HCMV in
tonsillar tissues. Notches represent interquartile ranges (IQRs) of the samples and whiskers the range
1.5 IQRs from the upper and lower quartiles.
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(maximum of six) (32). Moreover, a greater number of targets can increase cross-
reactions between primers and probes, hampering assay performance.
The new multiplex assay performed remarkably well on cell, plasma, and CSF
samples and mucocutaneous swabs as well as on palatine tonsils. HHV genopreva-
lences in this lymphoid organ have been reported to be highest for EBV (20.4 to 88.8%),
followed by HHV-7 (71.4%), HHV-6B (50.7%), HSV-1 (1.8 to 6.3%), and HCMV (0 to 5.4%)
(33–35), in line with our results. In addition, we frequently codetected several HHVs in
the same tonsil, a phenomenon only previously reported by Berger et al. for young
children (36).
HERQ-9 had good agreement with reference materials. The observed dissimilarities
were likely to be related to the types and sensitivities of different methodologies (e.g.,
viral culture, EIA, and spectrophotometry), sample processing (e.g., DNA extraction
methods), and the design of the PCR methods compared. Regarding the last item, the
primer and probe design, amplicon size, target gene and its polymorphisms, reagents,
and standards can all account for disagreements between qPCRs (37–39). In fact, these
discrepancies have urged the introduction of WHO international standards for EBV,
HCMV, and HHV-6B to increase the commutability between assays (39–42). However,
this has had only relative value since, even after standardization, the interlaboratory
variabilities continue to be high (up to 1.5 log10 IU/ml, on average) (39, 42).
Our findings emphasize the importance of multiplexing for comprehensive diagno-
sis and clinical management. Indeed, we identified additional HHVs in clinical samples
that had been tested only for a single pathogen, encountering several unforeseen
HSV-1 or VZV findings in mucocutaneous swabs, as well as EBV-HCMV coreactivations
in plasma of immunodeficient patients. In addition, we codetected other HHVs in
plasma in several combinations (EBV/HSV-1, EBV/HHV-6B, HCMV/HHV-6B, EBV/HCMV/
HSV-1, EBV/HCMV/HHV-6B, and EBV/HHV-6B/HSV-1). These coincidental discoveries,
also noted by others (4, 19, 43), may have a significant impact on risk assessment and
prognosis. Indeed, HHVs are thought to individually or synergistically contribute to viral
syndromes (5, 8, 44), organ rejection (19), or the development of cancer (45, 46).
Moreover, we found other HHVs besides HSV-1, HSV-2, or VZV in mucocutaneous
lesions (up to four in the same sample). The most common were EBV, HCMV, and
HHV-7, whose low viral loads were likely to represent skin virome (47) or latency in
TABLE 5 Three viral genomes intermixed into the same reactiona
Virus mix Estimated viral genome copies/l Measured viral genome copies/l
HSV-1 HSV-2 VZV HSV-1 HSV-2 VZV
1 1.1  106 5.6  103 2.8  102 1.2  106 (6) 1.0  104 (42) 1.9  102 (28)
2 1.3  104 5.9  104 3.4  101 1.3  104 (1) 6.3  104 (4) 1.4  101 (57)
3 1.2  103 6.2  103 4.2  104 1.1  103 (9) 5.1  103 (13) 2.7  104 (29)
4 1.2  102 4.5  101 4.2  103 1.1  102 (9) 7.2  101 (33) 3.3  103 (15)
5 1.1  105 4.6  101 3.6  104 1.1  105 (2) 8.9  101 (45) 3.0  104 (13)
6 1.2  102 5.9  104 4.2  104 1.6  102 (18) 4.9  104 (13) 4.2  104 (1)
EBV HCMV KSHV EBV HCMV KSHV
7 1.1  105 1.5  103 5.4  103 1.2  105 (5) 2.6  103 (37) 6.7  103 (15)
8 1.1  104 1.7  105 4.9  105 1.3  104 (12) 1.8  105 (4) 6.4  105 (20)
9 1.2  103 1.8  104 5.7  104 1.4  103 (10) 1.5  104 (11) 6.9  104 (14)
10 7.1  101 1.3  102 6.0  105 1.1  102 (31) 1.9  102 (26) 6.2  105 (2)
11 1.1  105 1.7  105 4.1  102 1.2  105 (6) 2.0  105 (12) 9.7  102 (57)
12 9.6  101 1.8  104 5.7  104 1.3  102 (22) 1.5  104 (14) 5.4  104 (3)
HHV6-A HHV6-B HHV-7 HHV6-A HHV6-B HHV-7
13 1.9  103 6.2  103 1.0  102 1.7  103 (9) 7.1  103 (9) 1.3  102 (24)
14 1.9  103 6.1  102 1.0  102 1.7  103 (10) 4.6  102 (18) 1.1  102 (10)
15 9.3  101 6.1  103 5.2  101 1.2  102 (21) 5.6  103 (6) 3.6  101 (25)
16 1.3  103 6.1  101 5.2  101 1.4  103 (9) 1.2  102 (47) 3.6  101 (26)
17 4.5  100 7.9  101 1.0  102 1.1  101 (58) 5.2  101 (30) 1.1  102 (4)
18 1.3  103 6.1  103 5.2  101 1.9  103 (27) 1.1  104 (40) 4.9  101 (4)
aOn the left are the estimated genome copies per dilution and on the right the copy numbers per microliter
of DNA extract quantified by HERQ-9. In parentheses are the coefficient of variations (percent) between the
estimated and measured copy numbers. Estimated and measured viral genome copies showed significant
correlation (Pearson’s r 0.996; P 0.01).
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mobilized leukocytes (48). Yet in a few samples, EBV DNA levels approached those of
HSV-1 or HSV-2, suggestive of in situ coreactivation or coinfection. Our detection of
both EBV and HSV-1 in mucocutaneous lesions and plasma supports an interplay
between these two viruses, as has been shown in vitro by Wu et al. (49). To the best of
our knowledge, we are the first to report on HHV co-occurrences in classical herpetic
lesions.
In conclusion, we demonstrated that HERQ-9 is suitable for the diagnosis of a
plethora of herpesvirus-related diseases. Besides its significance for clinical manage-
ment, the high sensitivity and specificity of this method will be of particular value for
studies of the human virome generally dealing with minute quantities of persisting
HHVs.
MATERIALS AND METHODS
Plasmids. Sequences of the reference strain (90 to 336 bp), including the corresponding qPCR
amplicon, were inserted into a pIDTSmart backbone (Integrated DNA Technologies). The plasmids
(pHSV-1, pHSV-2, pVZV, pHHV-6A, pHHV-6B, pHHV-7, pEBV, pHCMV, and pKSHV) were transformed into
Escherichia coli, extracted (see “DNA extraction” below), and confirmed with restriction analysis to contain
the correct insert (for whole insert sequences, see Text S1 in the supplemental material). The concen-
trations were measured spectrophotometrically, and the plasmids (diluted serially from 106 to 101
copies/l in 10 mM Tris-EDTA [TE] buffer) were stored at –80°C. In addition to single-plasmid analysis,
triple-plasmid combinations were made: pHSV-1, pHSV-2, and pVZV (pMIXI); pEBV, pHCMV, and pKSHV
(pMIXII); and pHHV-6A, pHHV-6B, and pHHV-7 (pMIXIII).
Plasmids containing the full-length or near-full-length genome of parvovirus B19 genotype 1 (50) and
polyomaviruses BKPyV (NC_001538) and JCPyV (NC_001699) (generous gifts from Eeva Auvinen) and
MCPyV (inserted in vector backbone pJ241, a gift from Patrick Moore [51]; Addgene plasmid 32059) were
used to test nonspecific amplification.
Infected cell cultures. Primers and probes were initially tested using viral DNA extracted from
virus-infected cell cultures. HSV-1 (strain F), HSV-2 (strain G), and VZV (strain Ellen) were propagated in
HaCat cells, human foreskin fibroblasts, and Vero cells; EBV was propagated in Raji cells, HCMV (strain
AD169) in human lung fibroblasts (MRC-5), HHV-6A (strain GS) in HSB-2 cells, HHV-6B (strain Z29) in
MOLT-3 cells, HHV-7 (strain JI) in SupT-1 cells, and KSHV (strain rKSHV.219) in latent and lytic iSLK.219 cells
(52).
Uninfected HaCaT cells were used for human DNA spiking experiments.
Prequantified reference material. All the reference materials are presented in Tables 3 and 4.
(i) Cell-free viral nucleocapsids. HSV-1 and HSV-2 nucleocapsids were isolated from pseudony-
mized dermal or mucosal lesion samples at the virus diagnostic unit of Turku University Hospital. The
viruses were initially typed by a rapid viral culture immunoperoxidase assay (53) and confirmed by HSV
type-specific gD (US6) gene-based PCR (54). For viral nucleocapsid DNA preparations, low-passage-
number stocks were generated in Vero cells (African green monkey kidney; ATCC), and the viral genomic
DNA was prepared as described previously (55, 56) (see Text S2 in the supplemental material for a more
detailed description). Two strains of HSV-1 (HSV-H1211 and HSV-H1215) and HSV-2 (HSV2-H12211 and
HSV2-H1526) were prepared and the viral copies determined spectrophotometrically to be used as
reference standards in dilutions of 1:10,000 and 1:100,000.
(ii) WHO international standards. WHO international standards for EBV, HCMV, and HHV-6B (NIBSC
codes 09/260, 09/162, and 15/266, respectively) (57–59) were tested undiluted and in dilutions of 1:10
and 1:100 with HERQ-9, to obtain conversion factors (viral DNA copies/international units).
(iii) KSHV genome in bacterial artificial chromosome (BAC). KSHV-BAC16 DNA (a generous gift
from Carolina Arias, University of California, Santa Barbara [UCSB], CA), derived from the KSHV strain of
primary effusion lymphoma (PEL) cell line JSC-1, was purified from E. coli (60). The viral copy numbers
were estimated spectrophotometrically. This reference was analyzed in dilutions of 1:10,000, 1:100,000,
and 1:1,000,000 with the multiplex assay.
(iv) Spiked sera. Serum samples spiked with HHV-6A (n 15) or HHV-6B (n 15) (4 106 to 4 102
copies/ml of serum) and HHV-7 (n 12) were obtained from the HHV-6 Foundation (Santa Barbara, CA).
Reference copy numbers given by the providing institute were used for HHV-6A and HHV-6B (59), while
the HHV-7 DNA was quantified with a commercial HHV-7 qPCR kit (PCRmax) in our laboratory.
(v) ATCC standard. Quantitative genomic DNA of VZV (ATCC VR1367DQ) was analyzed with HERQ-9
undiluted and at 1:10 and 1:100 dilutions.
Clinical samples. All the clinical HHV samples were collected at the virus diagnostic unit of Turku
University Hospital, and details are presented in Table 4. These included 80 mucocutaneous swab
samples, of which 35 were positive for HSV-1 and 30 for HSV-2 by rapid viral culture immunoperoxidase
assay (53), 25 mucocutaneous swab samples, of which 15 were positive for VZV by antigen enzyme
immunoassay (61), 5 HSV-1 and 4 HSV-2 PCR-positive DNA extracts from mucocutaneous swab samples
tested by a reference PCR (4, 31), and 8 CSF samples, of which 2 were VZV positive by a control PCR
(4, 31).
In addition, 60 plasma samples were investigated, of which 17 had been studied only for EBV
(GeneProof EBV PCR kit), 17 only for HCMV (GeneProof CMV PCR kit), and 26 for both. Of these, 13 and
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16 samples were reported as EBV and HCMV positive (200 copies/ml of plasma), respectively, while 9
and 5 had borderline copy numbers (50 to 200 copies/ml of plasma).
Tonsillar tissues. Altogether, 35 mechanically homogenized tonsillar tissues were screened for
the nine HHVs. The patients were 2 to 69 years of age (mean, 26), with eight 12 years (48). The viral
loads were normalized per 106 cells, determined with the human single-copy gene RNase P qPCR
(48).
Herpesvirus DNA mixes. Mixtures of three viral genomes extracted from the previously mentioned
infected cell lysates ([i] HSV-1, HSV-2, and VZV and [ii] EBV, HCMV, and KSHV) or spiked serum ([iii]
HHV-6A, -6B, and -7) were tested at uneven quantities, ranging from 4.5  100 to 1.1  106 copies/l of
DNA extract.
Primers and hydrolysis probes. Primers and probes were designed for all HHVs, except for EBV
(62). For each virus, several primer pairs were constructed in silico, in conserved genes (16, 18, 63,
64). Degenerate primers were designed for HCMV to cover polymorphisms in the target area.
Moreover, for HHV-6A, two probes were custom-designed to contain six locked nucleic acids (LNA)
each (for shorter probe length) and a single-nucleotide difference for specific binding to different
strains (Table 6).
The tendency of primers and probes to form secondary structures, primer dimers, and cross-dimers
was evaluated with Multiple Primer Analyzer (Thermo Fisher Scientific), while the propensity of the
amplicons to form secondary structures was checked with the Mfold web server. A BLAST search (65) was
performed to confirm primer binding to each of the virus strains in the nucleotide collection database
(NCBI).
Primer candidates designed in silico were tested at a 200 nM concentration with plasmid
dilutions (see “Plasmids” above), human DNA (HaCaT; 500 ng/reaction), and nuclease-free water in
a SYBR green format (Maxima SYBR green qPCR master mix; Thermo Fisher Scientific), followed by
melting-curve analysis. Primer pairs showing the highest efficiency and sensitivity with no primer
dimer formation were chosen for further testing with the hydrolysis probes. Concentrations of the
TABLE 6 Primers and probes
Virus
Oligonucleotide
name
Concn
(nM) Sequence (5=–3=)a
Positions of the amplicon
in the genome
(length)
Target
gene
Reference
sequence
(GenBank)
HSV-1 HSV-1 FWDLP1 300 GTTGAGCTAGCCAGCGA 93560–93683 (124 bp) UL42 X14112.1
HSV-1 REVLP1 300 CGTTAAGGACCTTGGTGAGC
HSV-1 probeLP1 250 FAM-CGCGAACTGACGAGCTTTGTG-BHQ1
HSV-2 HSV-2 FWD-2-2 400 CACACCACACGACAACAA 46783–46872 (90 bp) UL23 Z86099.2
HSV-2 REVLP1 400 TAGTTCAAACACGGAAGCC
HSV-2 probeLP1 200 JOE-CGGCGATGACGGCAATAAA-BHQ1
VZV VZV FWDLP1 200 GCGCAAGGCTATTAGAGC 48283–48145 (139 bp) ORF28 KU529566.1
VZV REVLP1 200 ACATGGCAGAAATCCCTG
VZV probeLP1 150 TxRd-CGCATACCCGGAAGTTCTTCAGAT-BHQ2
EBV EBV FWD 200 CGGAAGCCCTCTGGACTTC 153036–152947 (90 bp) BALF5 KF717093.1
EBV REV 300 CCCTGTTTATCCGATGGAATG
EBV Probe 300 FAM-TGTACACGCACGAGAAATGCGCC-BHQ1
HCMV H5 FWD211 400 GTGYTCCGTGAATCGTTAC 80396–80329 (68 bp) UL54 AB329634.1
H5 rev 211 500 AGTCKACCTCGATATCACAAGTCG
H5 Probe 20 300 TxRd-ACCCTGCTGCCGCCAGT-BHQ2
KSHV HHV8 fwd 3.1 200 ATATACGGCGACACTGACTC 13603–13761 (159 bp) ORF9 AP017458.1
HHV8 REV 10 200 GAGCAGAAGGCACTTGAAG
H8 Probe 300 200 JOE-CGGAGGAGCTAGCGTCAATCA-BHQ1
HHV-6A HHV6A FWD1-3 500 CGGCCTCCAGAGTTGTAA 133969–133894 (76 bp) U90 KP257584.1
HHV6A REV 10 500 TGTCCCTTCAACTACTGAATC
HHV6A LNA Probe A1 100 FAM-AC[	A]T[	G]TTGC[	T]A[	G]AAA[	G][	A]CT-BHQ1
HHV6A LNA Probe A2 100 FAM-AC[	A]T[	G]TTGC[	T]A[	C]AAA[	G][	A]CT-BHQ1
HHV-6B H6B FOTY1 300 TTTGACAGGAGTTGCTGAG 136176–136258 (83 bp) U90 AB021506.1
H6B ROTY 1 300 GGATTCAGGAAAAAGGTTCTAA
H6B PROBE MVP 200 JOE-AGGAAGCGTTTCGGTACACTTGGAG-BHQ1
HHV-7 HHV7 1. FWD 400 CTCGCAGATTGCTTGTTG 88332–88490 (159 bp) U57 AF037218.1
HHV7 1. REV 400 GCATACACCAACCCTACTGTAA
H7 MOP PROBE 300 TxRd-TTAGGCATCACGTTGGCATTG-BHQ2
aNucleotides in brackets refer to locked nucleic acids.
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primer pairs were optimized empirically with a matrix of reactions ranging from 100 nM to 600 nM.
The probes were tested in a 100 nM to 400 nM range. The final primer and probe concentrations are
presented in Table 6.
Primers and hydrolysis probes were purchased as high-performance liquid chromatography (HPLC)
purified except for two degenerative primers (HCMV), which were cartridge purified (Sigma-Aldrich). For
the triplex reactions, the probes were labeled with 6-carboxyfluorescein–black hole quencher 1 (FAM-
BHQ1), 6-carboxy-4=,5=-dichloro-2=,7=-dimethoxyfluorescein (JOE)-BHQ1, and sulforhodamine 101 acid
chloride-BHQ2 (TxRed).
Quantitative PCR protocol. Four commercial master mixes were pretested with HSV-1, HSV-2,
and VZV plasmids and viral genomes, with special consideration given to the performance in the
presence of human DNA and the coamplification of markedly low- and high-abundance targets.
Consequently, TaqPath ProAmp multiplex master mix (Thermo Fisher Scientific) was chosen for the
multiplex assay.
The qPCR thermal profile comprised initial denaturation at 95°C for 10 min followed by 45 cycles of
15 s at 95°C and 60 s at 60°C. The qPCRs contained 5 l of template, 2 TaqPath ProAmp multiplex
master mix, primers and probes (Table 6), and nuclease-free water in a final volume of 20 l. Water was
used as negative control in all the qPCR runs. The samples were run in duplicate in AriaMx real-time PCR
system (Agilent) and analyzed with Aria real-time PCR software (v.1.3) provided by the manufacturer. The
adaptive fluorescence baseline, efficiency, slope, R2 values, and intercept were calculated by the software.
Background-based threshold was set for cycles 5 to 9 for the FAM and Texas Red dyes and 8 to 11 for
the JOE dye.
Pretesting of primers in the SYBR green format consisted of the above-mentioned thermal profile,
followed by a melting-curve analysis at 95°C for 60 s, 45°C for 30 s, and 95°C for 30 s. The melting-curve
analysis was performed with a resolution of 0.5°C and soak time of 5 s.
DNA extraction. DNAs from plasma, mucocutaneous swabs, CSF, and WHO international standards
were extracted from 200 l of starting material with the QIAamp DNA blood minikit (Qiagen), DNAs from
cells and virus-infected cell lines were extracted with the QIAamp DNA minikit (Qiagen), DNA from KSHV
BAC was extracted with the NucleoBond Xtra Midi EF kit (Macherey-Nagel), and transformed plasmids
were extracted with GeneJET plasmid miniprep kit (Thermo Fisher Scientific), according to the manu-
facturers’ instructions. The final elution volumes were 100 l (with the exception of 50 l for plasma and
60 l for CSF samples). In every extraction, at least two negative controls (phosphate-buffered saline)
were included.
Analytical sensitivity and specificity. The analytical sensitivities were determined in singleplex and
multiplex formats using eight replicates of each HHV plasmid template in 50, 25, 15, 10, 5, 3, and 1 copy
per reaction. The proportion of positive results was fit into a generalized linear model using probit link
function (MATLAB v.R2018b) to approximate the limit of detection (LOD95) for a given target.
The analytical specificities were evaluated by cross-testing (i) 107 copies of viral genomic DNA
extracted from infected cell lysates and plasmid constructs of each HHV and (ii) plasmids containing near
full-length or full-length genomes of polyomaviruses BKPyV, JCPyV, and MCPyV and parvovirus B19
genotype 1. In addition, 1,000 ng of cellular DNA extracted from HaCaT cells and 500 ng from human
foreskin fibroblasts were tested for nonspecific amplification of human DNA.
Repeatability and reproducibility. The intra-assay and interassay variations were calculated using
three separate qPCR runs using five replicates of HHV plasmids (106 to 101 copies/l) in the singleplex
and multiplex formats, the latter both as single plasmids or in mixes pMIXI, pMIXII, and pMIXIII (106 to
101 copies/l). Two of the replicates were used to generate a standard curve, and three were marked as
unknowns. The standard deviations of the Cq values of the five replicates were used as a measure of
intra-assay variation. A coefficient of variation calculated from the copy numbers of unknown replicates
from three separate runs was used to estimate the interassay variation.
Statistical analysis. Boxplots were built with Rstudio (v.1.2.5001), and Excel 2016 (v.16.0.4964.1000)
was used to create scatterplot graphs. Pearson correlation coefficient between estimated and quantified
copies in virus mixes was calculated with SPSS (v.25). Venn diagrams were made with InteractiVenn (66).
Ethics statement. The Ethics Committee of the Helsinki and Uusimaa Hospital District approved the
collection of tonsils. Informed consent was obtained from all the donors or their parents prior to the
surgery.
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